Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma
The purpose of this study was evaluation the efficacy of antiepileptic drug carbamazepine in the treatment of mild-to-severe bronchial asthma.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Randomized, Placebo Controlled, Double Blind Study of Carbamazepine in Treatment of Bronchial Asthma|
- At 3 months of treatment: Change from baseline of the PEFR (also %predicted); Number of patients without asthma symptoms
- At 3 months of treatment: PEFR before and after salbutamol inhalation;
- Difference in PEFR pm-am (in %); The daily (daytime and night-time) symptoms scores; Use of other antiasthmatic medication
|Study Start Date:||August 1999|
|Estimated Study Completion Date:||April 2000|
Effective therapy of asthma still remains quite serious problem. According current opinion of leading specialists, asthma is an inflammatory disorder. But asthma also is a paroxysmal disorder: many specialists underline paroxysmal clinical picture of asthma. According to some authors, neurogenic inflammation may play important role in asthma mechanism. But migraine and trigeminal neuralgia are also neurogenic inflammatory paroxysmal diseases, and some antiepileptic drugs, like carbamazepine and valproates, are very effective in therapy of these diseases - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, we can suppose a possibility that some antiepileptic drugs also may show high efficacy in asthma therapy. Taken in consideration this hypothesis, we performed a double-blind, placebo-controlled 3-month trial for evaluation of carbamazepine efficacy in treatment of patients with mild-to-severe bronchial asthma.
Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00207428
|Principal Investigator:||Merab Lomia, MD, PhD||"Rea" Rehabilitation Centre|
|Study Director:||Manana Tchaia, MD||Centre of Chinese Medicine|